Zhong Jin Zai Xian·2025-12-03 06:46Core Insights - The respiratory infection drug market in China is projected to exceed 450 billion yuan by 2030, with a compound annual growth rate (CAGR) of 5.8% [1] - There is a significant gap in recovery medications for respiratory infections, which affects the overall development of the drug market [2][5] Market Overview - Nearly 300 million people in China are infected with respiratory diseases annually, with a cough prevalence rate exceeding 15% among urban and rural residents [1] - Current medications are heavily focused on prevention (vaccines, Vitamin C) and treatment (antiviral drugs, antibiotics), leaving a void in recovery phase medications [1] Product Development - The 999 Yiqi Qingfei Granules, developed by China Resources Sanjiu in collaboration with academician Zhang Boli, aims to address the recovery phase of respiratory infections [2][4] - The product has been launched on JD Health, allowing consumers to purchase it online [2] Quality Assurance - China Resources Sanjiu has established a comprehensive quality assurance system for the 999 Yiqi Qingfei Granules, ensuring safety and efficacy through confirmatory clinical studies [4] - The clinical trials demonstrated the drug's effectiveness in alleviating symptoms such as dry cough, fatigue, and shortness of breath during the recovery phase [4] Strategic Implications - The launch of 999 Yiqi Qingfei Granules fills a long-standing gap in the recovery medication market for respiratory infections, showcasing the unique value of modern traditional Chinese medicine [5] - This innovative drug is expected to become a new growth driver for China Resources Sanjiu, reinforcing its leading position in the respiratory drug market [5]